scanX
Caplin Point Laboratories
add_icon

Caplin Point Laboratories

1,727.80
+11.50
(0.67%)
Market Cap
13,133.30 Cr
PE Ratio
20.98
Volume
2,127.00
Day High - Low
1,731.20 - 1,710.30
52W High-Low
2,395.00 - 1,599.00
ann
Q3 Quarterly Results are out. Check out the updated financials9 hrs ago
Viewcross
right
hide
Key Fundamentals
Add Ratio
split_icon_default
Market Cap
13,133.30 Cr
EPS
70.57
PE Ratio
20.98
PB Ratio
4.13
Book Value
242.54
EBITDA
743.40
Dividend Yield
0.35 %
Industry
Healthcare
Sector
Pharmaceuticals
Return on Equity
18.75
Debt to Equity
0.00
Analyst Rating and Forecast
- By Refinitiv from2 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+100.00 %
+100.00 %
Hold
Hold0.0 %
0.0 %
Sell
Sell0.0 %
0.0 %
Forecast For
Actual

Company News

View All News
Caret
positive
Caplin Point Labs Q3 Net Profit Rises 17% YoYFeb 05, 2026
Caplin Point Laboratories reported consolidated net profit of ₹1.64 billion for Q3, marking a 17.14% increase from ₹1.40 billion in the same quarter last year, demonstrating strong financial performance.
positive
Caplin Point Labs Appoints Four New DirectorsFeb 03, 2026
Caplin Point Laboratories shareholders approved appointment of four new directors through postal ballot on January 31, 2026, including two Vice-Chairmen and two Independent Directors.
neutral
Caplin Point Labs Q3FY26 Earnings Call on Feb 5Jan 29, 2026
Caplin Point Laboratories announces post-results conference call scheduled for February 05, 2026 at 16:00 hrs IST to discuss Q3FY26 financial performance for quarter ended December 31, 2025.
View more

Peer Comparison Compare Peers on Screener

Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
Sun Pharmaceutical
1,704.10
#1 4,08,870.67
37.23
#1 54,729.00
9.71
#1 10,980
16.07
53.25
Divis Laboratories
6,126.00
1,62,626.05
65.90
9,712.00
18.67
2,191
-1.02
48.15
Torrent Pharmaceuticals
4,265.00
1,44,346.98
63.47
11,539.40
6.99
1,911
26.24
70.35
Cipla
1,345.00
1,08,645.31
24.16
28,409.50
7.12
5,291
-57.18
45.95
Dr Reddys Laboratories
1,261.10
1,05,255.23
19.18
33,741.20
16.73
5,725
-15.28
58.53
Lupin
2,249.10
1,02,738.62
21.74
22,909.50
13.74
3,306
#1 37.44
60.82
Zydus Life Science
911.35
91,703.13
#1 18.22
23,511.00
18.55
4,615
-0.32
52.96
Mankind Pharma
2,077.00
85,739.61
47.66
12,744.20
#1 20.90
2,007
7.65
45.43
Aurobindo Pharma
1,193.90
69,341.91
19.75
32,345.60
9.43
3,484
7.59
51.95
Alkem Laboratories
5,428.50
64,905.86
27.05
13,458.30
3.70
2,216
1.90
40.44

Automatic Screeners on ScanX

Community
10% near 52 Week Low
Growth Rate
Revenue Growth
15.50 %
Net Income Growth
17.27 %
Cash Flow Change
35.80 %
ROE
-4.63 %
ROCE
-2.26 %
EBITDA Margin (Avg.)
4.10 %

Quarterly Financial Results

Quarterly Financials
Mar 2015
Jun 2015
Sept 2015
Dec 2015
Mar 2016
Jun 2016
Sept 2016
Dec 2016
Mar 2017
Jun 2017
Sept 2017
Dec 2017
Mar 2018
Jun 2018
Sept 2018
Dec 2018
Mar 2019
Jun 2019
Sept 2019
Dec 2019
Mar 2020
Jun 2020
Sept 2020
Dec 2020
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Dec 2025
Revenue
64
71
78
81
84
87
98
105
122
127
135
144
146
148
163
167
190
197
234
239
235
247
270
280
288
310
312
336
351
360
376
386
401
407
431
453
471
478
504
524
528
533
564
577
Expenses
48
51
57
57
61
63
68
71
75
78
82
91
95
93
100
101
123
125
156
160
161
169
181
191
193
208
202
225
239
244
254
263
265
269
273
293
308
307
318
331
334
333
345
353
EBITDA
16
20
22
24
22
24
30
34
48
50
53
53
52
55
63
66
67
72
78
78
73
78
89
90
95
102
110
111
111
116
122
124
135
139
158
160
163
170
185
194
194
201
220
223
Operating Profit %
24 %
27 %
27 %
29 %
25 %
26 %
29 %
31 %
37 %
37 %
38 %
36 %
34 %
36 %
36 %
36 %
35 %
35 %
31 %
30 %
25 %
30 %
33 %
31 %
31 %
31 %
33 %
31 %
29 %
30 %
29 %
29 %
32 %
32 %
34 %
33 %
32 %
33 %
34 %
33 %
33 %
35 %
35 %
35 %
Depreciation
1
3
2
3
3
3
3
3
5
4
4
5
6
5
6
6
7
7
7
8
8
9
9
9
10
12
12
12
11
11
12
11
11
11
12
14
16
16
17
16
17
16
18
19
Interest
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Profit Before Tax
15
16
20
21
20
21
27
31
43
46
49
49
45
49
57
60
61
64
71
70
65
69
80
80
85
90
98
99
100
105
110
112
124
127
146
145
146
154
169
177
177
185
201
204
Tax
4
4
5
5
4
5
5
7
9
10
13
11
10
12
14
14
11
14
13
11
16
14
17
14
17
18
21
19
19
19
18
14
23
23
30
26
25
30
38
37
31
34
41
38
Net Profit
11
13
14
16
16
16
22
24
33
36
36
38
35
37
44
46
50
50
57
59
49
55
63
66
68
72
77
79
81
86
92
97
101
104
116
120
121
125
131
140
145
151
160
166
EPS in ₹
7.02
8.40
1.86
10.66
10.31
10.55
14.85
3.15
4.41
4.81
4.71
4.97
4.76
4.95
6.21
6.06
6.58
6.64
7.58
7.74
6.46
7.21
7.52
8.52
8.78
9.37
9.91
9.90
10.43
11.21
12.09
12.86
13.45
13.62
15.13
15.44
16.01
16.32
17.22
18.28
18.75
20.10
20.32
21.56
Above figures are in Rs. Crores

Balance Sheet

Balance Sheet
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total Assets
229
267
358
501
743
1,126
1,364
1,736
2,191
2,698
3,208
Fixed Assets
113
144
152
170
227
273
305
287
280
453
546
Current Assets
82
119
179
304
494
823
1,015
1,298
1,552
1,893
2,134
Capital Work in Progress
31
0
3
15
10
20
14
18
221
117
144
Investments
0
0
17
47
70
61
11
89
281
376
591
Other Assets
85
123
186
269
436
772
1,033
1,343
1,410
1,753
1,928
Total Liabilities
229
267
358
501
743
1,126
1,364
1,736
2,191
2,698
3,208
Current Liabilities
125
125
113
109
86
144
143
208
268
331
306
Non Current Liabilities
10
14
20
28
23
25
17
19
16
20
16
Total Equity
94
128
225
364
633
957
1,203
1,510
1,907
2,347
2,886
Reserve & Surplus
78
113
210
349
514
716
954
1,252
1,649
2,084
2,619
Share Capital
15
15
15
15
15
15
15
15
15
15
15
Above figures are in Rs. Crores

Cash Flow

Cash Flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Net Cash Flow
19
23
25
-14
74
70
215
-81
27
-39
61
Investing Activities
-23
-6
-36
-69
-100
-54
-30
-377
-216
-319
-333
Operating Activities
50
42
68
67
83
45
269
337
271
318
432
Financing Activities
-9
-14
-7
-12
90
80
-24
-41
-28
-38
-38
Above figures are in Rs. Crores

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Sept 2025
Dec 2025
Promoter
69.03 %
69.03 %
69.03 %
68.91 %
68.89 %
68.88 %
68.88 %
68.80 %
70.66 %
70.63 %
70.63 %
70.62 %
70.62 %
70.56 %
70.56 %
70.56 %
70.56 %
70.56 %
70.57 %
70.57 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
3.09 %
2.85 %
3.34 %
3.37 %
3.70 %
4.86 %
5.73 %
6.17 %
6.51 %
6.59 %
DIIs
1.28 %
1.44 %
1.14 %
1.16 %
1.20 %
1.07 %
1.12 %
1.12 %
0.65 %
0.26 %
0.20 %
0.43 %
1.09 %
1.49 %
1.84 %
2.11 %
2.01 %
2.22 %
2.10 %
2.05 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
22.94 %
21.69 %
20.93 %
20.79 %
20.79 %
20.76 %
19.00 %
18.91 %
18.73 %
18.57 %
18.31 %
18.36 %
17.59 %
17.50 %
17.12 %
15.77 %
15.11 %
14.32 %
14.20 %
14.13 %
Others
6.75 %
7.85 %
8.90 %
9.13 %
9.12 %
9.28 %
11.00 %
11.17 %
9.96 %
10.53 %
7.77 %
7.74 %
7.36 %
7.08 %
6.78 %
6.70 %
6.59 %
6.73 %
6.61 %
6.65 %
No of Share Holders
68,076
69,524
83,462
85,577
83,829
84,868
84,538
82,687
82,146
78,956
78,068
79,438
81,409
80,411
96,123
92,702
96,387
94,169
93,753
93,705

Dividend History

Annual Cash Flows 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Dividend Per Share (₹) 1.5 2 2.2 2.5 3 4 4.5 5 6 0.00
Dividend Yield (%) 0.26 0.5 0.78 0.62 0.44 0.68 0.34 0.25 0.35 0.00

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
19 May 2021 DIVIDEND Dividend
₹ 1.50 /share
 18 May 2021 523.80 624.30
21 Sept 2021 DIVIDEND Dividend
₹ 1.50 /share
 20 Sept 2021 860.80 864.15
24 May 2022 DIVIDEND Dividend
₹ 2.00 /share
 23 May 2022 667.95 745.95
22 Sept 2022 DIVIDEND Dividend
₹ 2.00 /share
 21 Sept 2022 815.55 719.05
09 Jun 2023 DIVIDEND Dividend
₹ 2.00 /share
 09 Jun 2023 736.75 809.00
14 Sept 2023 DIVIDEND Dividend
₹ 2.50 /share
 14 Sept 2023 950.60 1,000.20
31 May 2024 DIVIDEND Dividend
₹ 2.50 /share
 31 May 2024 1,352.10 1,291.45
23 Sept 2024 DIVIDEND Dividend
₹ 2.50 /share
 23 Sept 2024 1,541.65 1,939.60
30 Sept 2024 ANNUAL GENERAL MEETING Annual General Meeting
NA
 30 Sept 2024 1,541.65 1,911.50
07 Nov 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 07 Nov 2024 1,869.00 2,095.40
07 Feb 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 07 Feb 2025 2,030.95 2,177.05
15 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 15 May 2025 1,852.70 2,015.40
30 May 2025 DIVIDEND Dividend
₹ 3.00 /share
 30 May 2025 2,015.40 2,161.85
07 Aug 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 07 Aug 2025 2,085.70 1,929.60
12 Sept 2025 DIVIDEND Dividend
₹ 3.00 /share
 12 Sept 2025 1,929.60 2,237.60
22 Sept 2025 ANNUAL GENERAL MEETING Annual General Meeting
NA
 22 Sept 2025 1,929.60 2,343.00
05 Nov 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 05 Nov 2025 2,013.85 1,995.20
05 Feb 2026 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
 05 Feb 2026 1,721.50 1,909.65

Announcements

Announcement under Regulation 30 (LODR)-Earnings Call Transcript5 days ago
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeFeb 05, 2026
Announcement under Regulation 30 (LODR)-Investor PresentationFeb 05, 2026
Financial Results For The Quarter Ended December 31 2025Feb 05, 2026
Board Meeting Outcome for Outcome Of Board MeetingFeb 05, 2026
Announcement under Regulation 30 (LODR)-Change in ManagementFeb 03, 2026
Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportFeb 03, 2026
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJan 29, 2026
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJan 27, 2026
Board Meeting Intimation for Considering And Approving The Unaudited Financial Results For The Quarter And Nine Months Ended December 31 2025.Jan 27, 2026
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 14, 2026
Intimation Of Press Release On Acquisition Of AndasJan 01, 2026
Closure of Trading WindowDec 31, 2025
Shareholder Meeting / Postal Ballot-Notice of Postal BallotDec 31, 2025
Completion Of Inspection By INVIMA-Colombia At The Puducherry Injectables Facility Of The CompanyDec 12, 2025
Press Release On USFDA ApprovalDec 09, 2025
Intimation Of Press ReleaseDec 08, 2025
Acquisition Of Land By SubsidiaryNov 14, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptNov 12, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeNov 06, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementNov 05, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementNov 05, 2025
Un-Audited Standalone And Consolidated Financial Results For The Quarter And Half Year Ended 30Th September 2025Nov 05, 2025
Board Meeting Outcome for Outcome Of The Board MeetingNov 05, 2025
Board Meeting Intimation for Considering And Approving The Unaudited Financial Results Of The Company For The Quarter And Half-Year Ended September 30 2025Oct 29, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationOct 29, 2025
Board Meeting Intimation for Considering And Approving Inter-Alia The Unaudited Financial Results Of The Company For The Quarter And Half-Year Ended September 30 2025Oct 29, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseOct 23, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 04, 2025
Closure of Trading WindowSep 29, 2025
Shareholder Meeting / Postal Ballot-Scrutinizers ReportSep 23, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementSep 22, 2025
Shareholder Meeting / Postal Ballot-Outcome of AGMSep 22, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseSep 03, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationSep 01, 2025
Business Responsibility and Sustainability Reporting (BRSR)Aug 30, 2025
Notice Of 34Th Annual General Meeting Of The CompanyAug 30, 2025
Reg. 34 (1) Annual Report.Aug 30, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptAug 14, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeAug 07, 2025
Corporate Action-Board approves DividendAug 07, 2025
Financial Results For The Quarter Ended June 30 2025Aug 07, 2025
Board Meeting Outcome for Outcome Of The Board Meeting Held On August 7 2025Aug 07, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJul 30, 2025
Board Meeting Intimation for Board Of Directors Of The Company Will Be Held On Thursday August 07 2025 To Consider Inter-Alia Board Of Directors Of The Company Will Be Held On Thursday August 07 2025 To Consider Inter-AliaJul 30, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementJul 18, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 03, 2025
Closure of Trading WindowJun 27, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementJun 27, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationJun 26, 2025

Mutual Fund Holdings

Funding HouseCurrent Holding %1M Change1M Change %3M Change %Last 6M Trend
Samco Small Cap Fund Direct - Growth
0.00%
-18914
-2.57%
0.00%
JioBlackRock Nifty Smallcap 250 Index Fund Direct - Growth
0.19%
271
0.00%
-0.01%
DSP Nifty 500 Index Fund Direct-Growth
0.02%
12
0.02%
0.02%
DSP Nifty Smallcap 250 Index Fund Direct - Growth
0.19%
11
0.01%
0.19%
Navi Nifty MidSmallcap 400 Index Fund Direct - Growth
0.06%
3
0.00%
0.06%
Motilal Oswal BSE 1000 Index Fund Direct-Growth
0.02%
1
0.00%
0.00%
Mirae Asset Nifty Total Market Index Fund Direct-Growth
0.02%
0
0.00%
0.00%
Motilal Oswal Nifty Smallcap 250 Index Fund Direct - Growth
0.19%
0
0.00%
0.00%
Bandhan Nifty Smallcap 250 Index Fund Direct-Growth
0.19%
0
0.00%
0.01%
Bandhan Nifty 500 Momentum 50 Index Fund Direct-Growth
0.00%
0
0.00%
0.00%
DSP Nifty Smallcap250 Quality 50 Index Fund Direct - Growth
0.00%
0
0.00%
0.00%
Edelweiss Nifty Smallcap 250 Index Fund Direct - Growth
0.19%
0
0.00%
0.01%
Edelweiss Nifty500 Multicap Momentum Quality 50 Index Fund Direct-Growth
0.00%
0
0.00%
0.00%
Groww Nifty Smallcap 250 Index Fund Direct - Growth
0.19%
0
0.00%
0.00%
Groww Nifty Total Market Index Fund Direct - Growth
0.02%
0
0.00%
0.00%
HDFC BSE 500 Index Fund Direct - Growth
0.02%
0
0.00%
0.00%
HDFC Nifty Smallcap 250 Index Fund Direct-Growth
0.19%
0
0.00%
0.01%
HDFC Nifty500 Multicap 50:25:25 Index Fund Direct-Growth
0.05%
0
0.00%
0.00%
ICICI Prudential Nifty 500 Index Fund Direct-Growth
0.02%
0
0.00%
0.00%
ICICI Prudential Nifty Smallcap 250 Index Fund Direct - Growth
0.19%
0
0.00%
0.00%
ITI Pharma and Healthcare Fund Direct - Growth
0.88%
0
0.00%
0.02%
Bandhan BSE Healthcare Index Fund Direct-Growth
0.28%
0
0.00%
0.01%
Kotak Nifty Smallcap 250 Index Fund Direct-Growth
0.19%
0
0.00%
0.01%
Angel One Nifty Total Market Index Fund Direct - Growth
0.02%
0
0.00%
0.00%
Axis Nifty500 Momentum 50 Index Fund Direct-Growth
0.00%
0
0.00%
0.00%

Technical Indicators

RSI(14)
Neutral
39.10
ATR(14)
Less Volatile
59.90
STOCH(9,6)
Oversold
14.11
STOCH RSI(14)
Oversold
19.52
MACD(12,26)
Bearish
-6.37
ADX(14)
Weak Trend
24.67
UO(9)
Bearish
40.28
ROC(12)
Downtrend And Accelerating
-3.25
WillR(14)
Oversold
-93.97
Bearish
4
Neutral
3
Bullish
2

About Caplin Point Laboratories

Caplin Point Laboratories Limited is an Indian pharmaceutical company founded in 1990. It develops, produces, and markets generic formulations and branded products globally. The company has manufacturing facilities in India and serves markets in Latin America, Africa, the USA, and the European Union. Caplin Point specializes in various pharmaceutical formulations,...more
Website
https://www.caplinpoint.net
Chairperson NameC C Paarthipan
raisewe are part of Raise Financial Services
Heart
built with love

for indians who love to invest & trade

Explore   |   Sitemap
Fundamental Screeners
Technical Screeners
Intraday Screeners
Price & Volume Screeners
Candlestick Screeners
Bullish Stocks Today
Bearish Stocks Today
Stocks Nearing 52W High & Low
Rise & Fall Stocks
Index
Sector
Stock Heatmap
Companies
Sensex Companies
Nifty 50 Companies
Nifty Next 50 Companies
Nifty Bank Companies
Finnifty Companies
Defence Stocks
Semi Conductor Stocks
Renewable Energy Stocks
AI Stocks
Cement Stocks
Penny Stocks
Multibagger Stocks
Breakout Stocks
Dividend Stocks
Large Cap Stocks
Mid Cap Stocks
Small Cap Stocks
About Scanx

We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better.

Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians.
As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation. We plan to change that - a technology-led platform built for super traders and long term investors.

© 2025 - 2026 Raise Securities Pvt. Ltd. All rights reserved.

Part of Raise Financial Services

Registered Office: Unit No. 2201, 22nd Floor, Gold Medal Avenue, S.V. Road, Beside Patel Petrol Pump, Piramal Nagar, Goregaon West, Mumbai - 400104